Evidence map›Paper›PMID 26488496›Full record

ReviewTherapeutic delivery2015

Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Iason T Papademetriou, Tyrone Porter

Open access · greenAbstract readReview
In one paragraph

Review in Therapeutic delivery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  3. Review
  4. Review
  5. Review
  6. Diallyl disulfide in oncotherapy: molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Iason T PapademetriouDepartment of Mechanical Engineering, Boston University, Boston, MA 02215, USA.
Tyrone PorterDepartment of Mechanical Engineering, Boston University, Boston, MA 02215, USA.
Boston University · US

Funding

Enhancing ultra-sound-mediated tumor ablation with phase-shift nanoemulationR01EB016102 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI PORTER, TYRONE · 2013 to 2016
$1.8M
NIBIB NIH HHS NIH R01EB016102NIBIB NIH HHS R01 EB016102
6 · The paper itself

Abstract

Brain drug delivery is a major challenge for therapy of central nervous system (CNS) diseases. Biochemical modifications of drugs or drug nanocarriers, methods of local delivery, and blood-brain barrier (BBB) disruption with focused ultrasound and microbubbles are promising approaches which enhance transport or bypass the BBB. These approaches are discussed in the context of brain cancer as an example in CNS drug development. Targeting to receptors enabling transport across the BBB offers noninvasive delivery of small molecule and biological cancer therapeutics. Local delivery methods enable high dose delivery while avoiding systemic exposure. BBB disruption with focused ultrasound and microbubbles offers local and noninvasive treatment. Clinical trials show the prospects of these technologies and point to challenges for the future.

Indexed as

AnimalsAntineoplastic AgentsBlood-Brain BarrierBrain NeoplasmsChemistry, PharmaceuticalDrug Delivery SystemsHumansMedical OncologyAntineoplastic Agents

Identifiers

PMID26488496
PMCPMC4618388
OpenAlexW2117538553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.